X

Stay Connected

Sign Up for Updates

 
We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

New study finds more than half of brand medicine spending goes to the supply chain and others

By Brian Newell  |    January 7, 2022
More than half of total spending on brand medicines went to the supply chain, middlemen and other stakeholders in 2020 according to a new analysis from the Berkeley Research Group (BRG). These new...   Read More

Making medicines more affordable: Making insurance work like insurance

By Emilie Signora  |    December 8, 2021
Common-sense reforms can help ensure everyone benefits from America’s engine of innovation and receives the care they need and deserve. In this series, we’re taking a closer look at PhRMA’s...   Read More

What is missing in the current drug pricing plan

By Brian Newell  |    November 23, 2021
A recent congressional forum looked at the role pharmacy benefit managers (PBMs) play in determining what patients pay out of pocket for prescription medicines. The forum provided an important...   Read More

Insurance design barriers can impact patient adherence and can lead to poor health outcomes

By Cynthia Hicks  |    November 23, 2021
According to our inaugural Patient Experience Survey (PES), insurance design can jeopardize patients’ health due to access barriers to medicines.     Read More

ICYMI: PhRMA CEO speaks at STAT Summit about government price setting

By Andrew Powaleny  |    November 19, 2021
As part of the annual STAT Summit, PhRMA President and CEO Stephen J. Ubl recently spoke with STAT’s Matthew Herper to discuss the many unintended consequences expected from the latest drug...   Read More

Making medicines more affordable: Sharing savings at the pharmacy counter

By Emilie Signora  |    November 19, 2021
Common-sense reforms can help ensure everyone benefits from America’s engine of innovation and receives the care they need and deserve. In this series, we’re taking a closer look at PhRMA’s...   Read More

Three things to know about so-called Medicare negotiation polling

By Tom Wilbur  |    November 18, 2021
As policymakers continue to push partisan drug pricing proposals, several polls misrepresenting voter opinion have been circulated to try and justify these flawed policies. These polls fail to...   Read More

Making Medicines More Affordable: Making coupons count

By Emilie Signora  |    November 5, 2021
Common-sense reforms can help ensure everyone benefits from America’s engine of innovation and receives the care they need and deserve. In this series, we’re taking a closer look at PhRMA’s...   Read More

What they are saying: Government price setting for medicines is not the answer

By Sarah Sutton  |    November 4, 2021
America’s biopharmaceutical companies continue to voice the dangers of current proposals in Washington that would allow the government to set prices for medicines. While it’s being called...   Read More

Four things to know from IQVIAs latest report

By Katie Koziara  |    October 29, 2021
As the debate in Washington continues on drug pricing, it’s important that policymakers take into account what is actually happening in the market for medicines. Here are four things about...   Read More

Search the Catalyst

View Posts by Topic

see all

View Posts by Contributor

View Posts by Date

see all

Subscribe to Email Updates